Cue Biopharma Q2 EPS $(0.29) Beats $(0.30) Estimate, Sales $1.38M Beat $1.21M Estimate
Portfolio Pulse from sunil@benzinga.com
Cue Biopharma reported Q2 earnings per share (EPS) of $(0.29), beating the analyst consensus estimate of $(0.30) by 3.33%. This is a 21.62% increase over losses from the same period last year. The company also reported quarterly sales of $1.38 million, beating the analyst consensus estimate of $1.21 million by 14.21%. This is a 5.22K% increase over sales from the same period last year.
August 09, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cue Biopharma's Q2 earnings and sales beat analyst estimates, showing significant YoY growth. This could positively impact the company's stock in the short term.
Cue Biopharma's Q2 earnings and sales exceeded analyst estimates, which is generally seen as a positive signal by the market. The significant YoY growth in both earnings and sales also indicates strong financial performance, which could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100